PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
AnaSpec, EGT Group

Press Release


Receive press releases from AnaSpec, EGT Group: By Email RSS Feeds:

AnaSpec Introduces BAFF Protein


San Francisco, CA, October 07, 2010 --(PR.com)-- AnaSpec is pleased to announce the release of a recombinant human BAFF protein. Naïve B-cells, treated with 20-1000 ng/ml BAFF protein prepared by AnaSpec, has been showing increased IgG secretion compared to 2 leading commercial sources.

BAFF (BlyS, TALL-1, THANK, TNFSF13B, zTNF4) belongs to the TNF superfamily of proteins and is expressed by myeloid cells.1-4 It is a 285-amino acid long type II transmembrane protein, with the soluble152-amino acid active region.1-4 BAFF plays a pivotal role in B-cells homeostasis including survival of immature B-cells, transition of B-lymphocytes from T1 to T2 stage, and causes increase of antibodies secretion by B-cells.1-4

The sequence (Accession # NP_006564) corresponding to the extracellular domain of human BAFF along with a 6x His tag was expressed in E. coli. Recombinant human BAFF was purified from urea denatured bacterial lysate using immobilized metal affinity chromatography (IMAC) and refolded into its active state using a proprietary technique. The molecular weight of the recombinant human BAFF is 17.2 kDa. Containing less than 0.1 EU of endotoxin per 1 μg of protein as determined by LAL assay, the activity of BAFF was determined by its ability to stimulate production of immunoglobulin molecules such as IgG, IgA, and IgM in isolated mouse B-lymphocytes. Purified recombinant human BAFF is supplied as sterile and frozen condition at 0.1 mg/ml in 1 x PBS buffer with 5 mM DTT, pH=7.5.

References:

Batten, M. et. al. (2000) J Exp Med 192 (10): 1453-1465
Parry, TJ. et. al. (2001) J Pharm Exp Ther 296 (2): 396-404
Shan, X. et. al. (2006) Physiol Res 55: 301-307
Katsenelson, N. et. al. (2007) Eur J Immunol 37: 1785-1795

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

For more information visit www.anaspec.com

About Eurogentec

Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.

Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

For more information visit www.eurogentec.com

###
Contact Information
AnaSpec, Inc.
Tiffany Kao
510-791-9560
Contact
www.anaspec.com

Click here to view the list of recent Press Releases from AnaSpec, EGT Group
Promote Your Business